Elenco degli articoli con argomento «psoriasi»
Dermatologia23 mar 2021
Are biologics combined with methotrexate better
To investigate if the combination of biologics with methotrexate (MTX)
15 feb 2021
Skin Barrier Function in Psoriasis and Atopic Dermatitis
Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components.
09 feb 2021
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Psoriasis is a chronic inflammatory disease characterised by sharply demarcated erythematous and scaly skin lesions accompanied by systemic manifestations.
13 gen 2021
Celastrol: un approccio dermocosmetico alla psoriasi da scoprire
Il Celastrol, ed il ruolo dell’emolliente nella psoriasi
15 dic 2020
La scienza dermocosmetica scopre una nuova molecola per la psoriasi
Studi recenti hanno evidenziato che il Celastrol agisce sui mediatori dell’infiammazione tipica della psoriasi
14 dic 2020
Immune checkpoint-mediated psoriasis
A multicentric European study of 115 patients from European Network for Cutaneous ADverse Event to Oncologic drugs (ENCADO) group
24 nov 2020
Characteristic of Chronic Plaque Psoriasis Patients Treated with Biologics in Italy during the COVID-19 Pandemic
Risk Analysis from the PSO-BIO-COVID Observational Study
03 nov 2020
Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis
Biologics are modern immunomodulatory drugs, whose use in the treatment of psoriasis has led to remarkable results in psoriatic patients. The administration of these agents in special population groups, such as patients with chronic infections and renal impairment, as well as perioperative, pregnant or lactating patients, has not been thoroughly addressed, mostly because these patients are excluded from clinical studies.
20 ott 2020
Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach
With biologic drugs dominating the therapeutic space for severe immune‐mediated inflammatory disease, it is critical for clinicians to be familiar with the concept of drug immunogenicity, with the potential for our patients to develop anti‐drug antibodies (ADA) of clinical relevance.
15 ott 2020
L’infiammazione “nascosta” della psoriasi
Nelle fasi pre e post lesionali non si vede, ma si può comunque contrastare?
15 ott 2020
L’infiammazione Subclinica Nella Psoriasi
L’infiammazione subclinica della cute psoriasica pre- e post-lesionali: un nuovo ambito di intervento
11 ott 2020
No increased risk of melanoma among patients with psoriasis treated with methotrexate
Patients with an impaired immune system have higher risk for melanoma, the most dangerous type of skin cancer, and a worse prognosis.
11 ott 2020
New jak inhibitors for the treatment of psoriasis and psoriatic arthritis
Psoriasis is a common inflammatory skin disease that can be associated with various pathological conditions among which arthritis is a frequent comorbidity.
14 set 2020
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab
Is the risk of severe cardiovascular events increased after the initiation of treatment with the anti–interleukin 12/23p40 (IL-12/23p40) monoclonal antibody ustekinumab?
06 ago 2020
Eliminare il glutine dalla dieta mi fa guarire dalla psoriasi?
E’ vero che…..Eliminare il glutine dalla dieta mi fa guarire dalla psoriasi?
29 giu 2020
Where you live matters: Regional differences in health care resource use for psoriasis in the United States
It is unknown which U.S. Census region offers the best access to health care resources.
22 giu 2020
Treatment persistence in paediatric and adolescent psoriasis patients followed into young adulthood
from topical to systemic treatment – a prospective, longitudinal, observational cohort study of 448 patients
15 giu 2020
Treatment of erythrodermic psoriasis with biologics
A systematic review
10 giu 2020
Monografia SIDeMaST - METOTREXATO PSORIASI
Decenni dopo la sua introduzione, il Metotrexato (MTX) rimane ancora un farmaco fondamentale nell’armamentario terapeutico della psoriasi, dell’artrite psoriasica e, in generale, delle malattie infiammatorie croniche immuno-mediate cutanee.
24 mag 2020
Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases
A Systematic Review and Meta-analysis